Moreover, additional use of cetuximab with platinum/5-FU-based chemotherapy of 220 untreated recurrent or metastatic HNSCC patients significantly prolonged OS from 7.4 to 10.1 months in the group of patients who received chemotherapy plus cetuximab (108). Results of combined treatment with cetuximab and platinum/5-FU chemotherapy suggested that blocking the EGFR pathway by cetuximab is a potential way to improve the therapeutic effects of chemotherapy (Figure 3D, Table 2). Here, EGFR is linked to head and neck squamous cell carcinoma.